Form 4: Guardant Health CTO Sells Shares Under 10b5-1 Plan

Guardant Health's Chief Technology Officer, Darya Chudova, reported the pre-planned sale of 5,451 shares of common stock for approximately $104.04 per share.

Summary

• Darya Chudova, Chief Technology Officer of Guardant Health, Inc. (GH), reported the sale of company common stock.
• The transaction involved the disposition of 5,451 shares of common stock.
• The shares were sold at a weighted average price of $104.0418 per share, with individual sales ranging from $104.0401 to $104.0900.
• Following this transaction, Chudova beneficially owns 7,012 shares of Guardant Health common stock.
• The transaction is scheduled for December 15, 2025, and was made pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled.

Sentiment

Score: 5

Explanation: A neutral score is assigned as this is a routine insider sale under a 10b5-1 plan, which is generally not indicative of significant positive or negative company-specific news. While an insider sale reduces direct ownership, the pre-planned nature mitigates negative sentiment.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than an immediate reaction to new information, which is a common practice for corporate insiders.

Negatives

• An insider sale, even if pre-planned, reduces management's direct equity stake in the company, which can sometimes be perceived neutrally to slightly negatively by some investors.

Risks

• Potential for negative investor sentiment if the sale is misinterpreted as a lack of confidence, despite being a pre-planned transaction under a Rule 10b5-1 plan.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, focusing solely on an insider stock transaction.

Management Comments

• The filing includes a standard undertaking by the Reporting Person to provide full information regarding the number of shares sold at each separate price within the reported range, upon request.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies and does not inherently reflect broader industry trends or competitive dynamics. It is specific to the individual's personal financial planning.

Comparison to Industry Standards

• Insider sales are common across all industries for executives managing their personal portfolios.
• The execution under a Rule 10b5-1 plan aligns with best practices for corporate insiders to manage their equity holdings while mitigating concerns about trading on material non-public information. No specific comparable companies or projects are relevant for this type of individual transaction.

Stakeholder Impact

• Shareholders: May observe a slight reduction in direct insider ownership, though the 10b5-1 plan context typically lessens concerns about the implications of the sale.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider stock transaction.

Next Steps

• The filing does not specify any future actions or milestones for the company, beyond the reporting person's undertaking to provide detailed transaction information upon request.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned insider sale by the Chief Technology Officer under a Rule 10b5-1 plan. Such transactions are common for executives managing personal finances and are generally not considered a strong signal for the company's future performance or a reason to alter an investment thesis. The sale itself does not provide new material information to warrant a change in investment recommendation.

Keywords

Guardant Health, GH, Darya Chudova, Insider Sale, Form 4, SEC Filing, Chief Technology Officer, Stock Transaction, 10b5-1 Plan